Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 563

3.

Application of microvolt T-wave alternans testing in scheduling implantable cardioverter-defibrillator placement for the primary prevention of sudden cardiac death in patients with left ventricular dysfunction.

Daniłowicz-Szymanowicz L, Suchecka J, Zagożdżon P, Szwoch M, Kempa M, Raczak G.

Kardiol Pol. 2015;73(6):429-36. doi: 10.5603/KP.a2014.0216. Epub 2014 Nov 5.

4.

Microvolt T-wave alternans and other noninvasive predictors of serious arrhythmic events in patients with an implanted cardioverter-defibrillator.

Sredniawa B, Kowalczyk J, Lenarczyk R, Kowalski O, Sędkowska A, Cebula S, Musialik-Łydka A, Kalarus Z.

Kardiol Pol. 2012;70(5):447-55.

5.
6.

Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.

Lelakowski J, Piekarz J, Rydlewska A, Majewski J, Senderek T, Ząbek A, Małecka B.

Kardiol Pol. 2012;70(11):1099-110.

7.

Microvolt T-wave alternans for the risk stratification of dangerous ventricular arrhythmias in patients with previously implanted automatic cardioverter-defibrillator.

Lewandowski M, Kossuth I, Zielonka J, Wielusiński M, Kazimierczak A, Kornacewicz Jach Z, Przybycień K, Kaliszczak R.

Kardiol Pol. 2011;69(6):580-5.

8.

[Positive microvolt T-wave alternans as a marker of ventricular arrhythmia trigering during cardioverter-defibrillator implantation].

Wierzbowski R, Michałkiewicz D, Cholewa M, Jacewicz K, Gniłka A, Adamus J.

Pol Merkur Lekarski. 2006 Oct;21(124):310-3. Polish.

PMID:
17205766
9.

The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.

Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH 2nd, Sethuraman B, Dettmer MM, Rosenbaum DS; ABCD Trial Investigators.

J Am Coll Cardiol. 2009 Feb 10;53(6):471-9. doi: 10.1016/j.jacc.2008.08.077.

10.

[Prognostic value of microvolt level T-wave alternans in patients at high risk of sudden cardiac death].

Yang P, Guo T, Tang YM, Zhao L, Li SM, Liu ZM.

Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Jun;36(6):517-22. Chinese.

PMID:
19100065
11.

[Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients].

Piekarz J, Rydlewska A, Majewski J, Lelakowski J.

Pol Merkur Lekarski. 2012 Jun;32(192):368-73. Polish.

PMID:
22891561
12.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
13.

Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death.

Merchant FM, Ikeda T, Pedretti RF, Salerno-Uriarte JA, Chow T, Chan PS, Bartone C, Hohnloser SH, Cohen RJ, Armoundas AA.

Heart Rhythm. 2012 Aug;9(8):1256-64.e2. doi: 10.1016/j.hrthm.2012.03.014. Epub 2012 Mar 8.

14.

Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.

Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S.

J Am Coll Cardiol. 2006 Jul 4;48(1):112-21. Epub 2006 Jun 9.

15.

Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy.

Chow T, Kereiakes DJ, Bartone C, Booth T, Schloss EJ, Waller T, Chung ES, Menon S, Nallamothu BK, Chan PS.

J Am Coll Cardiol. 2006 May 2;47(9):1820-7. Epub 2006 Apr 19.

16.

Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction.

Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, Kaufman ES, Davidenko JM, Shinn TS, Fontaine JM.

J Am Coll Cardiol. 2006 Jan 17;47(2):456-63. Epub 2005 Dec 15.

17.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

18.

Evidence regarding clinical use of microvolt T-wave alternans.

Hohnloser SH, Ikeda T, Cohen RJ.

Heart Rhythm. 2009 Mar;6(3 Suppl):S36-44. doi: 10.1016/j.hrthm.2008.10.011. Epub 2008 Oct 11.

PMID:
19168396
19.

Predictive significance for sudden death of microvolt-level T wave alternans in New York Heart Association class II congestive heart failure patients: a prospective study.

Baravelli M, Salerno-Uriarte D, Guzzetti D, Rossi MC, Zoli L, Forzani T, Salerno-Uriarte JA.

Int J Cardiol. 2005 Oct 20;105(1):53-7.

PMID:
16207545
20.

Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.

Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM.

Int J Technol Assess Health Care. 2009 Apr;25(2):151-60. doi: 10.1017/S0266462309090205. Epub 2009 Mar 31.

PMID:
19331707

Supplemental Content

Support Center